Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:561018.
doi: 10.1155/2012/561018. Epub 2012 Nov 5.

Mechanisms of action of topical corticosteroids in psoriasis

Luís Uva  1 , Diana Miguel, Catarina Pinheiro, Joana Antunes, Diogo Cruz, João Ferreira, Paulo Filipe
Affiliations

Mechanisms of action of topical corticosteroids in psoriasis

Luís Uva et al. Int J Endocrinol. 2012.

Abstract

Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1-3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient's needs and his/her expectations, prescribing to each patient the most suitable vehicle.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Topical therapy for management of psoriasis.
Figure 2
Figure 2
Anti-inflammatory, immunosuppressive, and vasoconstrictive effects of topical corticosteroids [13, 14].
Figure 3
Figure 3
Action of glucocorticoids in gene transcription (adapted from [15]).
Figure 4
Figure 4
Purpura, milia and rubeosis steroidica induced by superpotent topical corticosteroids.
Figure 5
Figure 5
Strategies to improve safety for long-term use of topical corticosteroids in psoriasis.
See this image and copyright information in PMC

References

    1. Saraceno R, Gramiccia T, Frascione P, Chimenti S. Calcipotriene/betamethasone in the treatment of psoriasis: a review article. Expert Opinion on Pharmacotherapy. 2009;10(14):2357–2365. - PubMed
    1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873. - PubMed
    1. Laws PM, Young HS. Topical treatment of psoriasis. Expert Opinion on Pharmacotherapy. 2010;11(12):1999–2009. - PubMed
    1. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology. 1985;13(3):450–456. - PubMed
    1. Lebwohl M. Psoriasis. The Lancet. 2003;361(9364):1197–1204. - PubMed

LinkOut - more resources